UK Markets closed
  • FTSE 100

    6,983.50
    +43.92 (+0.63%)
     
  • FTSE 250

    22,472.04
    +116.59 (+0.52%)
     
  • AIM

    1,248.13
    +4.22 (+0.34%)
     
  • GBP/EUR

    1.1515
    +0.0004 (+0.04%)
     
  • GBP/USD

    1.3784
    -0.0001 (-0.0041%)
     
  • BTC-GBP

    44,836.30
    -1,452.74 (-3.14%)
     
  • CMC Crypto 200

    1,397.85
    +16.90 (+1.22%)
     
  • S&P 500

    4,170.42
    +45.76 (+1.11%)
     
  • DOW

    34,035.99
    +305.10 (+0.90%)
     
  • CRUDE OIL

    63.37
    -0.09 (-0.14%)
     
  • GOLD FUTURES

    1,764.90
    -1.90 (-0.11%)
     
  • NIKKEI 225

    29,642.69
    +21.70 (+0.07%)
     
  • HANG SENG

    28,793.14
    -107.69 (-0.37%)
     
  • DAX

    15,255.33
    +46.18 (+0.30%)
     
  • CAC 40

    6,234.14
    +25.56 (+0.41%)
     

Infinity to Present at the H.C. Wainwright Global Life Sciences Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference, which is being held Tuesday, March 9th – Wednesday, March 10th, 2021.

The presentation will be available for on-demand listening at 7:00 am ET on Tuesday, March 9th, 2021 or via the following link: https://journey.ct.events/view/2f6707ba-a83b-4a2e-adef-7170771bc186

The webcast of the presentation can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.

About Infinity and Eganelisib

Infinity is a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc.
Doxil® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005284/en/

Contacts

Investor Relations:
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com